Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board

INOVIO PHARMACEUTICALS, INC.

CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.
Up to 70% of PSUs vest on INO-3107 milestones (FDA approval, launch, market share, sales) by 2025-2027.
Remaining 30% vest on relative TSR vs. Russell 2000 Biotech index June 2024-Dec 2027 (50%-150% of target).
Stockholders ratified Ernst & Young as auditor (11.1M for) and approved non-binding say-on-pay (3.0M for).
All eight director nominees elected with votes ranging 3.1M-3.8M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.